PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-aden...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Franzese, Elisena, Diana, Anna, Centonze, Sara, Pignata, Sandro, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7303974/
https://ncbi.nlm.nih.gov/pubmed/32596142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00782
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares